+---------------------------------+---+-------+--------+-----------------+
| # BIOGRAPHICAL SKETCH           |   |       |        |                 |
|                                 |   |       |        |                 |
| Provide the following           |   |       |        |                 |
| information for the key         |   |       |        |                 |
| personnel and other significant |   |       |        |                 |
| contributors in the order       |   |       |        |                 |
| listed on Form Page 2.\         |   |       |        |                 |
| Follow this format for each     |   |       |        |                 |
| person. **DO NOT EXCEED FOUR    |   |       |        |                 |
| PAGES.**                        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| NAME                            |   | POS   |        |                 |
|                                 |   | ITION |        |                 |
| Marchand, Christophe            |   | TITLE |        |                 |
|                                 |   |       |        |                 |
|                                 |   | NCI   |        |                 |
|                                 |   | Staff |        |                 |
|                                 |   | Scie  |        |                 |
|                                 |   | ntist |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| eRA COMMONS USER NAME           |   |       |        |                 |
|                                 |   |       |        |                 |
| marchanc                        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| EDUCATION/TRAINING *(Begin with |   |       |        |                 |
| baccalaureate or other initial  |   |       |        |                 |
| professional education, such as |   |       |        |                 |
| nursing, and include            |   |       |        |                 |
| postdoctoral training.)*        |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| INSTITUTION AND LOCATION        | D |       | Y      | FIELD OF STUDY  |
|                                 | E |       | EAR(s) |                 |
|                                 | G |       |        |                 |
|                                 | R |       |        |                 |
|                                 | E |       |        |                 |
|                                 | E |       |        |                 |
|                                 |   |       |        |                 |
|                                 | * |       |        |                 |
|                                 | ( |       |        |                 |
|                                 | i |       |        |                 |
|                                 | f |       |        |                 |
|                                 | a |       |        |                 |
|                                 | p |       |        |                 |
|                                 | p |       |        |                 |
|                                 | l |       |        |                 |
|                                 | i |       |        |                 |
|                                 | c |       |        |                 |
|                                 | a |       |        |                 |
|                                 | b |       |        |                 |
|                                 | l |       |        |                 |
|                                 | e |       |        |                 |
|                                 | ) |       |        |                 |
|                                 | * |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| University of Reims, France     | B |       | 198    | Cellular        |
|                                 | . |       | 9-1992 | Biology         |
|                                 | S |       |        |                 |
|                                 | . |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
| University of Cambridge, UK     |   |       | 199    | Molecular       |
|                                 |   |       | 1-1996 | Pharmacology    |
+---------------------------------+---+-------+--------+-----------------+
| University of Paris, France     | P |       | 199    | Molecular       |
| (Pierre et Marie Curie)         | h |       | 5-1997 | Pharmacology    |
|                                 | . |       |        |                 |
|                                 | D |       |        |                 |
|                                 | . |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+
|                                 |   |       |        |                 |
+---------------------------------+---+-------+--------+-----------------+

**A. Positions and Honors**

**[Positions and Employment]{.underline}**

1996. Intern*,* Laboratory of Molecular Pharmacology, Department of
      Pharmacology, University of Cambridge (UK)

1995-1997 Ph.D. Student, Laboratory of Biophysics, INSERM U.201, CNRS
U.A.481, Muséum National d'Histoire Naturelle, Paris (France)

1998-2003 Visiting Fellow, Laboratory of Molecular Pharmacology, Center
for Cancer Research, NCI

2003-2005 Research Fellow, Laboratory of Molecular Pharmacology, Center
for Cancer Research, NCI

2005-2006 Research Associate, Laboratory of Molecular Pharmacology,
Center for Cancer Research, NCI

2006-Pres. Staff Scientist, Laboratory of Molecular Pharmacology, Center
for Cancer Research, NCI

**[Other Experience and Professional Memberships]{.underline}**

2007-Pres. Steering Committee, NCI Center for Excellence in HIV and
Cancer Virology

**[Honors]{.underline}**

1998 National Institutes of Health Visiting Program Fellowship Award

2002-2008 NCI Federal Technology Transfer Awards

2007 NCI Director's Intramural Innovation Award

**B. Selected peer-reviewed publications (42 out of 50) and patents**

**[Publications]{.underline}**

1.  **Marchand C,** Bailly C, McLean MJ, Moroney SE and Waring MJ (1992)
    The 2-amino group of guanine is absolutely required for specific
    binding of the anti-cancer antibiotic echinomycin to DNA. *Nucleic
    Acids Research, 20*, 5601-5606

2.  Bailly C, **Marchand C** and Waring MJ (1993) New binding sites for
    antitumor antibiotics created by relocating the purine 2-amino group
    in DNA. *Journal of the American Chemical Society, 115*, 3784-3785

3.  Zhou BW, **Marchand C,** Asseline U, Thuong NT, Sun JS, Garestier T
    and Hélène C (1995) Recognition of alternating
    oligopurine/oligopyrimidine tracts of DNA by oligonucleotides with
    base-to-base linkages. *Bioconjugate Chemistry, 6*, 516-523

4.  Bailly C, **Marchand C,** Nguyen CH, Bisagni E, Garestier T, Hélène
    C and Waring MJ (1995) Localized chemical reactivity in
    double-stranded DNA associated with the intercalative binding of
    benzo-e-pyridoindole and benzo-g-pyridoindole
    triple-helix-stabilizing ligands. *European Journal of Biochemistry,
    232,* 66-76

5.  **Marchand C,** Bailly C, Nguyen CH, Bisagni E, Garestier T, Hélène
    C and Waring MJ (1996) Stabilization of triple helical DNA by a
    benzopyridoquinoxaline intercalator. *Biochemistry, 35,* 5022-5032

6.  Nguyen CH, **Marchand C,** Delage S, Sun JS, Garestier T, Hélène C
    and Bisagni E (1998) Synthesis of 13*H*-benzo\[6,7\]- and
    13*H*-benzo\[4,5\]indolo\[3,2-*c*\]-quinolines: a new series of
    potent specific ligands for triplex DNA. *Journal of the American
    Chemical Society, 120*, 2501-2507

7.  **Marchand C,** Sun JS, Bailly C, Waring MJ, Garestier T and Hélène
    C (1998) Optimization of alternate-strand triple helix formation at
    the ^5'^CpG^3'^ and ^5'^GpC^3'^ junction steps. *Biochemistry, 37,*
    13322-13329

8.  Baudoin O, **Marchand C,** Teulade-Fichou MP, Vigneron JP, Sun JS,
    Garestier T, Hélène C and Lehn JM (1998) Stabilization of DNA triple
    helices by crescent-shaped dibenzophenanthrolines. *Chemistry-A
    European Journal, 4,* 1504-1508

9.  Zain R\*, **Marchand C\*,** Sun JS, Nguyen CH, Bisagni E, Garestier
    T and Hélène C (1999) Design of a triple-helix-specific cleaving
    reagent. *Chemistry & Biology, 6,* 771-777, ***\*Equal
    contribution***

10. **Marchand C,** Nguyen CH. Ward B, Sun JS, Bisagni E, Garestier T
    and Hélène C (2000) A new family of sequence-specific DNA cleaving
    agents directed by triple-helical structures: Benzopyridoindole-EDTA
    conjugates. *Chemistry-A European Journal, 6,* 1559-1563

11. Neamati N, **Marchand C** and Pommier Y (2000) HIV-1 Integrase
    inhibitors: past, present and future. *Advances in Pharmacology,
    49,* 147-165

12. Jing N, **Marchand C,** Liu J, Mitra R, Hogan ME and Pommier
    Y (2000) Mechanism of inhibition of HIV-1 integrase by G-tetrad
    forming oligonucleotides *in vitro*. *Journal of Biological
    Chemistry, 275,* 21460-21467

13. Pilon A, **Marchand C**, Kavlick MF, Owen J, Bajaj K, Mitsuya H and
    Pommier Y (2000) Mutations in the HIV-1 integrase of patients
    receiving long-term dideoxynucleoside therapy do not confer
    resistance to AZT. *AIDS Research and Human Retroviruses, 16,*
    1417-1422

14. Pommier Y, **Marchand C** and Neamati N (2000) Retroviral integrase
    inhibitors year 2000: update and perspectives. *Antiviral Research,
    47,* 139-148

15. **Marchand C**, Neamati N and Pommier Y (2001) In vitro HIV-1
    integrase assays. *Methods in Enzymology, 340,* 624-633

16. Neamati N, **Marchand C**, Winslow HE and Pommier Y (2001) Human
    Immunodeficiency Virus type 1 integrase-targeted inhibitor design.
    *Antiretroviral Therapy,* *5*, 87-103

17. Jing N, **Marchand C,** Guan Y, Liu J, Pallansch LR, Lackman-Smith
    C, De Clercq E and Pommier Y (2001) Structure-activity of inhibition
    of HIV-1 integrase and virus replication by G-quartet
    oligonucleotides. *DNA and Cell Biology, 20,* 499-508

18. **Marchand C,** Pourquier P, Laco G, Jing N and Pommier Y (2002)
    Interaction of Topoisomerase I with G-quartet-forming and G-rich
    oligodeoxy- and oligoribonucleotides. *Journal of Biological
    Chemistry, 277,* 8906-8911

19. **Marchand C,** Zhang X, Pais GCG, Cowansage K, Neamati N, Burke TR
    Jr and Pommier Y (2002) Structural determinants for HIV-1 integrase
    inhibition by ß-diketo acids. *Journal of Biological Chemistry,
    277,* 12596-12603

20. Pais GCG, Zhang X, **Marchand C,** Neamati N, Cowansage K,
    Svarovskaia E, Pathak VK, Tang Y, Nicklaus M, Pommier Y and Burke TR
    Jr (2002) Structure activity investigation of 3-aryl-1,3-diketo
    containing compounds as HIV-1 integrase inhibitors. *Journal of
    Medicinal Chemistry, 45,* 3184-3194

21. **Marchand C,** Johnson AA, Karki RG, Pais GCG, Zhang X, Cowansage
    K, Patel TA, Nicklaus M, Burke TR Jr and Pommier Y (2003) Metal
    selectivity and resistance of the soluble double-mutant integrase
    (F185K/C280S) for HIV-1 integrase inhibition by ß-diketo acids.
    *Molecular Pharmacology, 64,* 600-609

22. Krajewski K, Long YQ, **Marchand C**, Pommier Y and Roller PP (2003)
    Design and synthesis of dimeric HIV-1 integrase inhibitory peptides.
    *Bioorganic & Medicinal Chemistry Letters,* *13,* 3203-3205

23. Zhang X, **Marchand C,** Pommier Y and Burke TR Jr (2004) Design and
    synthesis of photoactivatable aryl diketo acid-containing HIV-1
    integrase inhibitors as potential affinity probes. *Bioorganic &
    Medicinal Chemistry Letters, 14,* 1205-1207

24. Johnson AA, **Marchand C** and Pommier Y (2004) HIV-1 integrase
    inhibitors: a decade of research and two drugs in clinical trial.
    *Current Topics in Medicinal Chemistry*, *4,* 671-686

25. Krajewski K, **Marchand C**, Long YQ, Pommier Y and Roller PP (2004)
    Synthesis and HIV-1 integrase inhibitory activity of dimeric and
    tetrameric analogs of indolicidin. *Bioorganic & Medicinal Chemistry
    Letters, 14,* 5595-5598

26. Pommier Y and **Marchand C** (2005) Interfacial inhibitors of the
    protein-nucleic acid interactions. *Current Medicinal Chemistry --
    Anti Cancer Agents.* *5,* 421-429

27. Pommier Y, Johnson AA and **Marchand C** (2005) Integrase inhibitors
    to treat HIV/AIDS. *Nature Reviews Drug Discovery.* *4,* 236-248

28. Johnson AA, Santos W, Pais GC, **Marchand C**, Amin R, Burke TR,
    Verdine G and Pommier Y (2006) Integration requires the donor DNA
    end (5'-C) interaction with glutamine 148 of the HIV-1 integrase
    flexible loop. *Journal of Biological Chemistry, 261*, 461-467

29. **Marchand C**, Antony S, Kohn KW, Cushman M, Ioanoviciu A, Staker
    BL, Burgin AB, Stewart L and Pommier Y (2006) A novel
    norindenoisoquinoline structure reveals a common interfacial
    inhibitor pardigm for ternary trapping of the topoisomerase I-DNA
    covalent complex. *Molecular Cancer Therapeutics, 5,* 1-9

30. Di Santo R, Costi R, Roux A, Artico M, Lavecchia A, Marinelli L,
    Novellino E, Palmisano L, Andreotti M, Amici R, Galluzzo CM,
    Nencioni L, Palarma AT, Pommier Y and **Marchand C** (2006) Novel
    bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase
    inhibitors: design, synthesis, biological activities and mechanism
    of action. *Journal of Medicinal Chemistry, 49,* 1939-1945

31. Semenova E, Johnson AA, **Marchand C**, Davis DA, Yarchoan R and
    Pommier Y (2006) Preferential inhibition of the magnesium-dependent
    strand transfer reaction of HIV-1 integrase by α-hydroxytropolones.
    *Molecular Pharmacology*, *69*, 1454-1460

32. **Marchand C**, Johnson AA, Semenova E and Pommier Y (2006)
    Mechanisms and inhibition of HIV integration. *Drug Discovery Today:
    Disease Mechanisms, 3,* 253-260

33. Semenova E, Johnson AA, **Marchand C** and Pommier Y (2006)
    Integrase inhibitors. *Current Opinions in HIV and AIDS, 1,* 380-387

34. **Marchand C**, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R,
    Roller P, Kvaratskhelia M and Pommier Y (2006) Covalent binding of
    the natural antimicrobial peptide indolicidin to DNA abasic sites.
    *Nucleic Acids Research,* *34,* 5157-5165

35. Johnson AA\*, **Marchand C\*,** Patil S, Costi R, Di Santo R, Burke
    TR and Pommier Y (2007) Probing HIV-1 integrase inhibitor binding
    sites with position-specific integrase-DNA crosslinking assays.
    *Molecular Pharmacology*, *71,* 893-901, ***\*Equal contribution***

36. **Marchand C** and Pommier Y (2007) A novel norindenoisoquinoline
    structure reveals a common interfacial inhibitor paradigm for
    ternary trapping of the topoisomerase I-DNA covalent complex. *CCR
    Newsletter, Frontiers in Science*, *6,* 1-5

37. Antony S\*, **Marchand C\***, Stephen AG, Thibaut L, Agama KK,
    Fisher RJ and Pommier Y (2007) Novel high-throughput
    electrochemiluminescent assay for identification of human
    tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization
    of furamidine (NSC 305831) as an inhibitor of Tdp1. *Nucleic Acids
    Research,* *35*, 4474-4484, ***\*Equal contribution***

38. Liao C, Karki RG, **Marchand C**, Pommier Y and Nicklaus M (2007)
    Virtual screening application of a model of full-length HIV-1
    integrase complexed with viral DNA. *Bioorganic & Medicinal
    Chemistry Letters, 17,* 5361-5365

39. **Marchand C**, Beutler JA, Warimu A, budihas S, Möllman U, Heinisch
    L, Mellors JW, Le Grice SF and Pommier Y (2008) madurahydroylactones
    derivatives as dual inhibitors of human immunodeficiency virus type
    1 integrase and RNase H. . *Antimicrobial Agents and Chemotherapy,*
    *52*, 361-364

40. Semenova AA, **Marchand C** and Pommier Y (2008) HIV-1 integrase
    inhibitors: update and perspectives. *Advances in Pharmacology, 56,*
    199-228

41. Marinello J, **Marchand C**, Mott BT, Bain A, Thomas CJ,
    Pommier Y. (2008) Comparison of raltegravir and elvitegravir on
    HIV-1 integrase catalytic reactions and on a series of
    drug-resistant integrase mutants. *[Biochemistry]{.underline}*. 47:
    9345-54

42. Di Santo R, Costi R, Roux A, Miele G, Crucitti GC, Iacovo A, Rosi F,
    Lavecchia A, Marinelli L, Di Giovanni C, Novellino E, Palmisano L,
    Andreotti M, Amici R, Galluzzo CM, Nencioni L, Palamara AT, Pommier
    Y, **Marchand C**. (2008) Novel quinolinonyl diketo acid derivatives
    as HIV-1 integrase inhibitors: design, synthesis, and biological
    activities. *[J. Med. Chem.]{.underline}* 51: 4744-50

**[Patents]{.underline}**

1.  International Patent Application *\#* WO 03/049695 A2 (2003) \[DHHS#
    E-317-2001\] "Compounds to treat HIV infection and AIDS". Terrence
    Burke, Xuechun Zhang, Godwin Pais, Evguenia Svarovskaia, Vinay
    Pathak, **Christophe Marchand** and Yves Pommier. *[The Government
    of the United States of America.]{.underline}*

2.  International Patent Application \# WO 05/087759 (2004) \[DHHS#
    E-187-2003\] "Quinolin-4-ones as Inhibitors of Retroviral Integrase
    for the Treatment of HIV, AIDS and AIDS Related Complex (ARC)". Yves
    Pommier, **Christophe Marchand**, Roberto Di Santo, Marino Artico
    and Roberta Costi. *[The Government of the United States of
    America]{.underline}*

3.  US Provisional Patent Application \# 60/534,378 (2004) \[DHHS#
    E-039-2004\] "Peptide inhibitors of HIV-1 integrase useful for the
    treatment of retroviral and HIV infections". Peter Roller,
    **Christophe Marchand**, Krysztof Krajewski, Vinay Pathak, Yijun
    Zhang and Yves Pommier. *[The Government of the United States of
    America]{.underline}*

4.  US Provisional Patent Application #60/741,769 (2005) \[DHHS#
    E-308-2005\] "Discovery of tropolone Inhibitors of HIV-1 Integrase
    that can be Used for the Treatment of Retroviral Infection,
    Including AIDS" Yves Pommier, **Christophe Marchand**, Elena
    Semenova and Allison Johnson. *[The Government of the United States
    of America]{.underline}*

5.  US Provisional Patent Application \# 60/786,746 (2006) \[DHHS#
    E-097-2006\] "Tetracycline Inhibitors of Human Tyrosyl-DNA
    Phosphodiesterase (Tdp1) for the Treatment of Cancers" Yves Pommier,
    **Christophe Marchand** and Laurent Thibaut. *[The Government of the
    United States of America]{.underline}*

6.  US Provisional Patent Application \# 60/786,604 (2006) \[DHHS#
    E-165-2006\] "Diamidines Inhibitors of Human Tyrosyl-DNA
    Phosphodiesterase (Tdp1) for the Treatment of Cancers" Yves Pommier,
    **Christophe Marchand** and Laurent Thibaut. *[The Government of the
    United States of America]{.underline}*

7.  US Provisional Patent Application \# 60/849,718 (2006) \[DHHS#
    E-264-2006\] "Discovery of stilbenedisulfonic acid derivatives as
    inhibitors of HIV-1 integrase that can be used for the treatment of
    retroviral infection including AIDS" Yves Pommier, **Christophe
    Marchand**, Elena Semenova. *[The Government of the United States of
    America]{.underline}*

8.  US Provisional Patent Application \[DHHS \#
    E-130-2007-0-US-01\] (2007) "Steroid compounds, compositions and
    methods of treatment" Yves Pommier, **Christophe Marchand**, Smitha
    Antony, Thomas Dexheimer. *[The Government of the United States of
    America]{.underline}*

9.  US Provisional Patent Application \# 61/042,706 (2008) \[DHHS#
    E-121-2008\] "Protein tyrosine phosphatase inhibitors of human
    tyrosyl-DNA phosphodiesterase (Tdp1) and methods of treating
    disorders" Yves Pommier, **Christophe Marchand**, Anton Simeonov,
    Thomas Dexheimer, Wendy Lea, James Inglese, Chris Austin and Ajit
    Jadhav. *[The Government of the United States of
    America.]{.underline}*

**C. Research Support**

Intramural Research Program, Center for Cancer Research, NCI.